G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 73 filers reported holding G1 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,715 | -99.5% | 3,274 | -98.2% | 0.00% | -100.0% |
| Q2 2022 | $887,000 | +194.7% | 179,472 | +353.2% | 0.00% | +100.0% |
| Q1 2022 | $301,000 | +11.1% | 39,600 | +49.3% | 0.00% | 0.0% |
| Q4 2021 | $271,000 | -66.4% | 26,516 | -55.9% | 0.00% | -50.0% |
| Q3 2021 | $807,000 | +78.1% | 60,133 | +138.7% | 0.00% | +100.0% |
| Q4 2020 | $453,000 | -90.7% | 25,188 | -94.0% | 0.00% | -90.9% |
| Q3 2020 | $4,888,000 | +6.5% | 423,211 | +123.7% | 0.01% | 0.0% |
| Q2 2020 | $4,589,000 | +769.1% | 189,166 | +295.2% | 0.01% | +450.0% |
| Q1 2020 | $528,000 | +15.8% | 47,870 | +139.2% | 0.00% | +100.0% |
| Q3 2019 | $456,000 | +714.3% | 20,015 | +992.5% | 0.00% | – |
| Q2 2019 | $56,000 | +64.7% | 1,832 | -10.2% | 0.00% | – |
| Q1 2019 | $34,000 | +70.0% | 2,039 | +98.3% | 0.00% | – |
| Q4 2018 | $20,000 | -99.5% | 1,028 | -98.6% | 0.00% | -100.0% |
| Q3 2018 | $3,926,000 | +67.7% | 75,076 | +39.4% | 0.01% | +28.6% |
| Q2 2018 | $2,341,000 | – | 53,859 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |